The Burden of Hospital-Associated Venous Thromboembolism

Slides:



Advertisements
Similar presentations
Enhanced Recovery in Thoracic Surgery Referral Managing pre- existing medical conditions Informed decision making Pre-operative Health & risk assessment.
Advertisements

Venous Thromboembolism Prevention August Venous Thromboembloism Prevention 2 Expected Practice  Assess all patients upon admission to the ICU for.
Venous Thromboembolism (VTE) Prophylaxis Policy Mary-Anne Davies Patient Safety Specialist Accreditation Coordinator.
Beverley Hunt Simon Noble Hospital Acquired Venous Thromboembolism.
The Health Roundtable 3-3c_HRT1215-Session_HANNAFORD_UNSW_NSW How many people received appropriate VTE prophylaxis? Presenter: Natalie Hannaford UNSW Innovation.
Development and Testing of a Risk Assessment Model for Venous Thrombosis in Medical Inpatients: The Medical Inpatients and Thrombosis (MITH) Study Score.
Chapter Three Venous Disease Coalition Epidemiology of VTE Risks, Risk Factors VTE Toolkit.
Peri-operative management of anticoagulation Marc Carrier MD, MSc FRCPC Assistant Professor, University of Ottawa Associate Scientist, Ottawa Health Research.
Hospital acquired VTE Alert system Caroline Baglin Thrombophilia CNS.
Risk assessment for VTE
Prevention of Venous Thromboembolism 8 th ACCP Guidelines Chest 2008.
Peter Davies Senior Pharmacist.  Venous thromboembolic prevention is a DH patient safety priority  NICE clinical guideline venous thromboembolism reducing.
Preventing Hospital Acquired Thrombosis Simon Noble Peggy Edwards.
Surgical Care Improvement Project Prevention of Post-operative Venous Thromboembolism Team Membership Department of Surgery, Nursing, General Medicine,
Rivaroxaban for Prevention of Venous Thromboembolism After Total Knee Arthroplasty: Impact on Healthcare Costs Based on the RECORD3 Study Kwong L, Lees.
VTE prevention and anticoagulation practice VTE prevention and anticoagulation practice Mr A McSorley Lead Thrombosis Nurse RCHT.
Qmentum ROPs: Tips and Tools for Implementation in Your Organization Teague Lamarche & Greg Kennedy Canadian Patient Safety Officer Course Ottawa, Ontario.
Surgical Care Improvement Project Prevention of Post-operative Venous Thromboembolism Team Membership Department of Surgery, Nursing, General Medicine,
What still needs to be achieved in the clinical situation? VTE Symposium – sharing good practice 21 st September 2010 Dr Tamara Everington.
Risk assessment for VTE Dr Roopen Arya King’s College Hospital.
Risk Assessment for VTE. Which of the following best describes you?
Higher Incidence of Venous Thromboembolism (VTE) in the Outpatient versus Inpatient Setting Among Patients with Cancer in the United States Khorana A et.
Mandatory Training: VTE prevention and anticoagulation practice Mandatory Training: VTE prevention and anticoagulation practice Mr A McSorley Lead Thrombosis.
Surgical Care Improvement Project Prevention of Post-operative Venous Thromboembolism Team Membership Department of Surgery, Nursing, Pharmacy, CCE Confidential:
Dabigatran Etexilate is Effective and Safe for the Extended Prevention of Venous Thromboembolism Following Total Hip Replacement Eriksson BI, Dahl OE,
Oral Rivaroxaban Compared with Subcutaneous Enoxaparin for Extended Thromboprophylaxis After Total Hip Arthroplasty: The RECORD1 Trial Eriksson BI, Borris.
Educational Purposes. Coalition To Prevent VTE - Risk Assessment.
Orthopaedic Thromboprophylaxis: Experience from Derriford Hospital
Insert name of presentation on Master Slide Hospital Acquired Thrombosis Simon Noble and Mike Fealey.
VTE prophylaxis Sharif-Kashani,B.MD SBMU Preventing VTE Over 12 million people in the United States are at risk of VTE due to hospitalization for major.
Thrombosis.TV Breaking Update: Betrixaban Approved by the FDA
Volume 134, Issue 3, Pages (September 2014)
Venous Thromboembolism Prophylaxis (VTE)
APEX Trial design: Patients hospitalized with an acute medical illness were randomized to oral betrixaban for days (n = 3,759) versus subcutaneous.
Dr.H.Chandrashekar, Dr.A.Chaudhuri, Dr. A. Douglas, Dr. D. Lowdon
Copyright © 2012 American Medical Association. All rights reserved.
Ortho Warfarin Dosing Protocol
Silent No More:.
OBMC Core Measures January 2015
NOACs in Clinical Practice: Are They All the Same?
New Strategies to Prevent CV Events After Hospital Discharge
The Safety and Efficacy of Full vs
Global Burden of VTE. Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care.
Selecting NOACs for High-Risk Patients
The effectiveness of anticoagulant and antiplatelet agents in preventing venous thromboembolism during stroke rehabilitation: a historical cohort study.
New Oral Anticoagulants and VTE Management
Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.
Evaluating New Therapies in HF
Don't look now! Risk stratify first
Succinct Review of the New VTE Prevention and Management Guidelines
Treatment of Thromboembolic Disease The Need for Multiple Perspectives
Deep venous thrombosis after repair of nonruptured abdominal aneurysm
Tools to Address Adherence Issues in Patients With SIHD
Anticoagulation and Thrombosis Management
Identifying High-Risk AF Patients
Trials and Tribulations in VTE: How Do Real-World Data Fit In?
Cancer-Associated Thrombosis
New Strategies to Reduce HF Readmissions
Optimizing Joint Health in Hemophilia

An Unmet Need.
Volume 135, Issue 2, Pages (February 2009)
Disease Burden of VTE Phases of VTE Treatment.
At the Crossroads of Coagulation
Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.
Cumulative prevalence of venous thromboembolic events in ITP patients who underwent splenectomy compared with those who did not. Cumulative prevalence.
Preventing Venous Thromboembolism Participating Hospital Survey
Deep venous thrombosis after repair of nonruptured abdominal aneurysm
The CHA(2)DS2-(VASc) stroke risk and HAS-BLED bleeding risk index are calculated by totalling the scores for each risk factor present.68–71 The lower graph.
Presentation transcript:

The Burden of Hospital-Associated Venous Thromboembolism

Thrombosis Causes 1 in 4 Deaths Globally

Thrombosis Is a Major Contributor to Global Disease Burden

Disease Burden of VTE in the United States

Economic Burden of VTE

Risk Factors for VTE Occurrence Within 3 Months of Medical Illness or Major Surgery

Independent VTE Risk Factors

VTE Risk Does Not Stop After Hospitalization

Cumulative Probability of VTE After Admission of Medically Ill Patients

Mandated VTE Risk Assessment in Hospitals

Failures of a Universal VTE Risk Assessment Strategy in Medically Ill

Common Areas of Failure for VTE Prophylaxis in the Hospital Setting

Risk Assessment and Prophylaxis Strategy

VTE Risk Assessment Tools

APEX Risk Factors for VTE at Baseline

APEX Rate of Stroke or TIA

MARINER Study Design

New Paradigm in Medically Ill Thromboprophylaxis: Individualized (Patient-Level)

Postoperative Risk-Stratified VTE Prevention

Extended VTE Prophylaxis Following Total Hip or Knee Arthroplasty (EPCAT II)

High-Risk Features for VTE

Conclusion

Abbreviations

Abbreviations (cont)